Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study

Br J Haematol. 2023 Jun;201(6):1192-1199. doi: 10.1111/bjh.18734. Epub 2023 Mar 15.

Abstract

The Children's Oncology Group AHOD0831 study used a positron emission tomography (PET) response-adapted approach in high-risk Hodgkin lymphoma, whereby slow early responders (SERs) received more intensive therapy than rapid early responders (RERs). We explored if baseline PET-based characteristics would improve risk stratification. Of 166 patients enrolled in the COG AHOD0831 study, 94 (57%) had baseline PET scans evaluable for quantitative analysis. For these patients, total body metabolic tumour volume (MTV), total lesion glycolysis (TLG), maximum standardized uptake value (SUVmax ) and peak SUV (SUVpeak ) were obtained. MTV/TLG thresholds were an SUV of 2.5 (MTV2.5 /TLG2.5 ) and 40% of the tumour SUVmax (MTV40% /TLG40% ). TLG2.5 was associated with event-free survival (EFS) in the complete cohort (p = 0.04) and in RERs (p = 0.01), but not in SERs (p = 0.8). The Youden index cut-off for TLG2.5 was 1841. Four-year EFS was 92% for RER/TLG2.5 up to 1841, 60% for RER/TLG2.5 greater than 1841, 74% for SER/TLG2.5 up to 1841 and 79% for SER/TLG2.5 greater than 1841. Second EFS for RER/TLG2.5 up to 1841 was 100%. Thus, RERs with a low baseline TLG2.5 experienced excellent EFS with less intensive therapy, whereas RERs with a high baseline TLG2.5 experienced poor EFS. These findings suggest that patients with a high upfront tumour burden may benefit from intensified therapy, even if they achieve a RER.

Keywords: Hodgkin disease; Hodgkin's lymphoma; PET; metabolic tumor volume; total lesion glycolysis.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child
  • Fluorodeoxyglucose F18 / metabolism
  • Glycolysis
  • Hodgkin Disease* / diagnostic imaging
  • Hodgkin Disease* / drug therapy
  • Hodgkin Disease* / pathology
  • Humans
  • Positron Emission Tomography Computed Tomography
  • Positron-Emission Tomography / methods
  • Prognosis
  • Radiopharmaceuticals
  • Retrospective Studies
  • Risk Assessment
  • Tumor Burden

Substances

  • Fluorodeoxyglucose F18
  • Radiopharmaceuticals